These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 1787505)

  • 1. Low dose methotrexate treatment in systemic sclerosis.
    van den Hoogen FH; Boerbooms AM; van de Putte LB; Rasker JJ; van Venrooij WJ
    J Rheumatol; 1991 Nov; 18(11):1763-4. PubMed ID: 1787505
    [No Abstract]   [Full Text] [Related]  

  • 2. Localized and systemic scleroderma show different histological responses to methotrexate therapy.
    Seyger MM; van den Hoogen FH; van Vlijmen-Willems IM; van de Kerkhof PC; de Jong EM
    J Pathol; 2001 Apr; 193(4):511-6. PubMed ID: 11276011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of oral methotrexate in the treatment of systemic sclerosis.
    Krishna Sumanth M; Sharma VK; Khaitan BK; Kapoor A; Tejasvi T
    Int J Dermatol; 2007 Feb; 46(2):218-23. PubMed ID: 17269983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indirect evidence for the efficacy of methotrexate in diffuse systemic sclerosis.
    Low AH; Lee P
    J Rheumatol; 2008 Nov; 35(11):2286. PubMed ID: 19004063
    [No Abstract]   [Full Text] [Related]  

  • 5. Photochemotherapy and methotrexate used to treat generalized cutaneous scleroderma.
    Ridge CA; Moktar A; Barry J; Murphy GM
    J Eur Acad Dermatol Venereol; 2007 May; 21(5):692-3. PubMed ID: 17447992
    [No Abstract]   [Full Text] [Related]  

  • 6. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma.
    Pope JE; Bellamy N; Seibold JR; Baron M; Ellman M; Carette S; Smith CD; Chalmers IM; Hong P; O'Hanlon D; Kaminska E; Markland J; Sibley J; Catoggio L; Furst DE
    Arthritis Rheum; 2001 Jun; 44(6):1351-8. PubMed ID: 11407694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stabilization of Microcirculation in Patients with Early Systemic Sclerosis with Diffuse Skin Involvement following Rituximab Treatment: An Open-label Study.
    Smith V; Pizzorni C; Riccieri V; Decuman S; Brusselle G; DE Pauw M; Deschepper E; Piette Y; Ruaro B; Sulli A; Vandecasteele E; Melsens K; DE Keyser F; Cutolo M
    J Rheumatol; 2016 May; 43(5):995-6. PubMed ID: 27134280
    [No Abstract]   [Full Text] [Related]  

  • 8. Successful treatment of systemic-sclerosis-related digital ulcers with a selective endothelin type A receptor antagonist (sitaxentan).
    Gholam P; Sehr T; Enk A; Hartmann M
    Dermatology; 2009; 219(2):171-3. PubMed ID: 19590168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Shifting our thinking about uncommon disease trials: the case of methotrexate in scleroderma.
    Johnson SR; Feldman BM; Pope JE; Tomlinson GA
    J Rheumatol; 2009 Feb; 36(2):323-9. PubMed ID: 19040308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Modification of B-cell precursor frequencies by systemic photochemotherapy (PUVA) in patients with systemic scleroderma].
    Kunzelmann V; Brenke A; Fetscher I; Lukowsky A; Leschik G; Adrian K; Sönnichsen N
    Z Arztl Fortbild (Jena); 1994 Aug; 88(7-8):519-24. PubMed ID: 7856255
    [No Abstract]   [Full Text] [Related]  

  • 11. Protective effect of pravastatin on vascular endothelium in patients with systemic sclerosis: a pilot study.
    Furukawa S; Yasuda S; Amengual O; Horita T; Atsumi T; Koike T
    Ann Rheum Dis; 2006 Aug; 65(8):1118-20. PubMed ID: 16837498
    [No Abstract]   [Full Text] [Related]  

  • 12. Predictors and outcomes of scleroderma renal crisis: data from the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial.
    Strand V
    Arthritis Rheum; 2002 Nov; 46(11):2836-7. PubMed ID: 12428222
    [No Abstract]   [Full Text] [Related]  

  • 13. [Use of antimetabolites in diseases of auto-aggression].
    Romiti N
    Hospital (Rio J); 1968 Jan; 73(1):71-8. PubMed ID: 5308511
    [No Abstract]   [Full Text] [Related]  

  • 14. [Prostaglandin E1 in progressive systemic scleroderma].
    Biltz H; Küster W; Lüders G; Wehrmann W; Kreysel HW
    Vasa Suppl; 1988; 23():138-40. PubMed ID: 3206331
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of the diseases of the dermis.
    Polano MK
    Arch Belg Dermatol Syphiligr; 1972; 28(1):59-73. PubMed ID: 4656306
    [No Abstract]   [Full Text] [Related]  

  • 16. Successful treatment of systemic sclerosis with topical PUVA.
    Morita A; Sakakibara S; Sakakibara N; Yamauchi R; Tsuji T
    J Rheumatol; 1995 Dec; 22(12):2361-5. PubMed ID: 8835578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of systemic sclerosis.
    Medsger TA
    Curr Opin Rheumatol; 1990 Dec; 2(6):956-9. PubMed ID: 2128028
    [No Abstract]   [Full Text] [Related]  

  • 18. Methotrexate treatment in scleroderma.
    van den Hoogen FH; Boerbooms AM; van de Putte LB
    Am J Med; 1989 Jul; 87(1):116-7. PubMed ID: 2741971
    [No Abstract]   [Full Text] [Related]  

  • 19. Therapeutic interventions in systemic sclerosis.
    van den Hoogen FH
    Neth J Med; 1998 Sep; 53(3):137-8. PubMed ID: 9803147
    [No Abstract]   [Full Text] [Related]  

  • 20. The role of DMARDs in systemic sclerosis therapy.
    Blank N; Max R; Lorenz HM
    Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii42-4. PubMed ID: 16987834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.